METHODOLOGICAL DEVELOPMENT OF QUANTITATIVE MRS OF THE BREAST

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 乳腺癌是一种非常常见的疾病，每8名美国妇女中就有1人在其一生中受到影响，每年造成4万多人死亡。开发新的非侵入性工具进行筛查、诊断、肿瘤分期和治疗监测，可以帮助提高患者护理质量。我们的研究小组先前已经证明，定量磁共振波谱可以用于早期指示肿瘤对治疗的反应。目前正在多中心临床试验（ACRIN 6657）中研究该方法的临床可行性。 该项目的目标是开发和评估乳腺癌定量磁共振波谱分析的改进方法。将开发几种新的MR波谱技术，并与标准ACRIN 6657 MRS方案进行比较。 该项目将分为两个阶段。第一阶段将在幻影和正常志愿者身上开发和比较这些序列。该阶段将持续约6个月，在该阶段结束时，我们将选择最有希望的序列变异。在这个阶段，我们估计我们将需要每周一次1.5小时的会议，共20周（30小时）。 在第二阶段，我们将对10名受试者进行正常重现性研究，每名受试者研究两次。采集方案将包括常规MRI，然后是标准ACRIN 6657 MRS采集，然后是实验MRS方法。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Breast cancer is a very common disease, affecting 1 in 8 American women in their lifetimes and causing more than 40,000 deaths each year. The development of new non-invasive tools for screening, diagnosis, tumor staging, and treatment monitoring can help improve the quality of patient care. It has been previously shown by our group that quantitative MR spectroscopy can be used to give an early indication of a tumor's response to therapy. The clinical feasibility of this methodology is currently being investigated in a multi-site clinical trial (ACRIN 6657). The goal of this project is to develop and evaluate improved methods for performing quantitative MR spectroscopy in breast cancer. Several new MR spectroscopy techniques will be developed and compared to the standard ACRIN 6657 MRS protocol. There will be two phases to this project. Phase I will develop and compare these sequences on phantoms and normal volunteers. This phase will last approximately 6 months, at the end of which we will select the most promising of the sequence variations. In this phase we estimate that we will need one 1.5-hour session per week for each of 20 weeks (30 hrs). In Phase II, we will perform a normal reproducibility study on a series of 10 subjects, each studied twice. The acquisition protocol will consist of conventional MRI, followed by the standard ACRIN 6657 MRS acquisition, then followed by the experimental MRS methods.